المساهمون: Masakazu Toi, Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Joohyuk Sohn, In Hae Park, Seock-Ah Im, Shin-Cheh Chen, Sotaro Enatsu, P Kellie Turner, Valérie A M André, Molly C Hardebeck, Sachi Sakaguchi, Matthew P Goetz, George W Sledge Jr, Sohn, Joo Hyuk

مصطلحات موضوعية: Aminopyridines / administration & dosage, Aminopyridines / adverse effects, Aminopyridines / pharmacokinetics, Anastrozole / administration & dosage, Anastrozole / adverse effects, Anastrozole / pharmacokinetics, Aromatase Inhibitors / administration & dosage, Aromatase Inhibitors / adverse effects, Aromatase Inhibitors / pharmacokinetics, Benzimidazoles / administration & dosage, Benzimidazoles / adverse effects, Benzimidazoles / pharmacokinetics, Breast Neoplasms / blood, Breast Neoplasms / drug therapy, Breast Neoplasms / genetics, Diarrhea / chemically induced, Diarrhea / epidemiology, Double-Blind Method, Drug Therapy, Combination, Female, Fulvestrant / administration & dosage, Fulvestrant / adverse effects, Fulvestrant / pharmacokinetics, Humans, Letrozole / administration & dosage, Letrozole / adverse effects, Letrozole / pharmacokinetics, Neutropenia / chemically induced, Neutropenia / epidemiology

العلاقة: CANCER SCIENCE; J00454; OAK-2022-05022; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190887Test; T9992022298; CANCER SCIENCE, Vol.112(6) : 2381-2392, 2021-06

الإتاحة: https://doi.org/10.1111/cas.14877Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190887Test

المساهمون: Patrick Neven, Stephen R D Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C Hurt, Antonio Llombart-Cussac, George W Sledge, Sohn, Joo Hyuk

مصطلحات موضوعية: Aminopyridines / administration & dosage, Antineoplastic Agents, Hormonal / administration & dosage, Benzimidazoles / administration & dosage, Breast Neoplasms / chemistry, Breast Neoplasms / drug therapy, Breast Neoplasms / pathology, Drug Combinations, Female, Fulvestrant / administration & dosage, Humans, Neoplasm Staging, Progression-Free Survival, Receptor, ErbB-2 / analysis, Treatment Outcome

العلاقة: CLINICAL CANCER RESEARCH; J00564; OAK-2022-04515; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190609Test; https://aacrjournals.org/clincancerres/article/27/21/5801/671728/MONARCH-2-Subgroup-Analysis-of-Patients-ReceivingTest; T202126210; CLINICAL CANCER RESEARCH, Vol.27(21) : 5801-5809, 2021-11

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-20-4685Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190609Test
https://aacrjournals.org/clincancerres/article/27/21/5801/671728/MONARCH-2-Subgroup-Analysis-of-Patients-ReceivingTest

المؤلفون: Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.

المصدر: Alves , C L , Ehmsen , S , Terp , M G , Portman , N , Tuttolomondo , M , Gammelgaard , O L , Hundebøl , M F , Kaminska , K , Johansen , L E , Bak , M , Honeth , G , Bosch , A , Lim , E & Ditzel , H J 2021 , ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ' , Nature Communications , vol. 12 , 5112 . https://doi.org/10.1038/s41467-021-25422-9Test

مصطلحات موضوعية: Breast Neoplasms/drug therapy, Cell Line, Tumor, Cyclin-Dependent Kinase 4/antagonists & inhibitors, Cyclin-Dependent Kinase 6/antagonists & inhibitors, Disease Progression, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Fulvestrant/administration & dosage, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors/administration & dosage, Proto-Oncogene Proteins c-akt/genetics

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/16ebb9be-b3ba-4857-9d6b-45c685175b25Test

الإتاحة: https://doi.org/10.1038/s41467-021-25422-9Test
https://portal.findresearcher.sdu.dk/da/publications/16ebb9be-b3ba-4857-9d6b-45c685175b25Test

المؤلفون: Pancholi, Sunil, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Nikitorowicz-Buniak, Joanna, Ressa, Anna, Gao, Qiong, Leal, Mariana Ferreira, Bhamra, Amandeep, Thornhill, Allan, Morisset, Ludivine, Montaudon, Elodie, Sourd, Laura, Fitzpatrick, Martin, Altelaar, Maarten, Johnston, Stephen R, Marangoni, Elisabetta, Dowsett, Mitch, Martin, Lesley-Ann

المساهمون: Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics

مصطلحات موضوعية: Animals, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Breast Neoplasms/genetics, Cell Line, Tumor, Cyclin-Dependent Kinase 4/genetics, Cyclin-Dependent Kinase 6/genetics, Drug Resistance, Neoplasm/drug effects, Female, Fulvestrant/administration & dosage, Humans, MCF-7 Cells, Mice, Inbred BALB C, Nude, Piperazines/pharmacology, Protein Kinase Inhibitors/pharmacology, Pyridines/pharmacology, RNA Interference, Receptors, Estrogen/genetics, Retinoblastoma Protein/genetics, Tamoxifen/administration & dosage, Xenograft Model Antitumor Assays/methods

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/410287Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/410287Test

المؤلفون: Jones, Robert, Casbard, Angela, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew, Howell, Sacha

المصدر: Jones , R , Casbard , A , Carucci , M , Cox , C , Butler , R , Alchami , F , Madden , T-A , Bale , C , Bezecny , P , Joffe , J , Moon , S , Twelves , C , Venkitaraman , R , Waters , S , Foxley , A & Howell , S 2020 , ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ' , The Lancet Oncology ....

مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Aromatase Inhibitors/pharmacology, Breast Neoplasms/drug therapy, Carcinoma, Ductal, Breast/drug therapy, Lobular/drug therapy, Double-Blind Method, Drug Resistance, Neoplasm/drug effects, Female, Follow-Up Studies, Fulvestrant/administration & dosage, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Recurrence, Local/drug therapy, Prognosis, Pyrimidines/administration & dosage, Pyrroles/administration & dosage, Receptors, Estrogen/metabolism, Salvage Therapy, Survival Rate, ResearchInstitutes_Networks_Beacons/mcrc

الإتاحة: https://doi.org/10.1016/S1470-2045Test(19)30817-4
https://research.manchester.ac.uk/en/publications/b253c20e-1d0d-4475-a468-3784a1027b23Test

المؤلفون: Alves, Carla Maria Lourenco, Elias, Daniel, Lyng, Maria Bibi, Bak, Martin, Ditzel, Henrik

المصدر: Alves , C M L , Elias , D , Lyng , M B , Bak , M & Ditzel , H 2018 , ' SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer ' , Breast Cancer Research , vol. 20 , 60 . https://doi.org/10.1186/s13058-018-0988-9Test

مصطلحات موضوعية: Endocrine resistance, Epithelial-mesenchymal transition, Estrogen receptor-positive breast cancer, Fulvestrant, SNAI2, Antineoplastic Agents, Hormonal/administration & dosage, Fulvestrant/administration & dosage, Humans, Middle Aged, Snail Family Transcription Factors/genetics, Neoplasm Metastasis, Estrogen Receptor alpha/genetics, MCF-7 Cells, Drug Resistance, Neoplasm/genetics, Epithelial-Mesenchymal Transition/drug effects, Adult, Female, Aged, Cell Proliferation/drug effects, Gene Expression Regulation, Neoplastic/genetics, Breast Neoplasms/drug therapy

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/c9785f56-a64a-4163-9f65-0137f9d9b5f1Test

الإتاحة: https://doi.org/10.1186/s13058-018-0988-9Test
https://portal.findresearcher.sdu.dk/da/publications/c9785f56-a64a-4163-9f65-0137f9d9b5f1Test
https://findresearcher.sdu.dk/ws/files/141819899/Alves_et_al_2018_Breast_Cancer_Research.pdfTest
https://rdcu.be/01iVTest

المؤلفون: Caffa, Irene, Spagnolo, Vanessa, Vernieri, Claudio, Valdemarin, Francesca, Becherini, Pamela, Wei, Min, Brandhorst, Sebastian, Zucal, Chiara, Driehuis, Else, Ferrando, Lorenzo, Piacente, Francesco, Tagliafico, Alberto, Cilli, Michele, Mastracci, Luca, Vellone, Valerio G, Piazza, Silvano, Cremonini, Anna Laura, Gradaschi, Raffaella, Mantero, Carolina, Passalacqua, Mario, Ballestrero, Alberto, Zoppoli, Gabriele, Cea, Michele, Arrighi, Annalisa, Odetti, Patrizio, Monacelli, Fiammetta, Salvadori, Giulia, Cortellino, Salvatore, Clevers, Hans, De Braud, Filippo, Sukkar, Samir G, Provenzani, Alessandro, Longo, Valter D, Nencioni, Alessio

المساهمون: CMM Sectie Molecular Cancer Research, Child Health, Regenerative Medicine and Stem Cells, Cancer, Hubrecht Institute with UMC

مصطلحات موضوعية: Animals, Biological Factors/blood, Breast Neoplasms/diet therapy, Diet Therapy/methods, Diet, Healthy/methods, Disease Models, Animal, Disease Progression, Drug Resistance, Neoplasm/drug effects, Early Growth Response Protein 1/metabolism, Fasting/physiology, Female, Fulvestrant/administration & dosage, Humans, Insulin-Like Growth Factor I/metabolism, Insulin/blood, Leptin/blood, MCF-7 Cells, Mice, Inbred NOD, SCID, PTEN Phosphohydrolase/metabolism, Piperazines/administration & dosage, Pyridines/administration & dosage, Receptors, Estrogen, Progesterone, Tamoxifen/adverse effects

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/441128Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/441128Test

المؤلفون: Slamon, Dennis J., Neven, Patrick, Chia, Stephen, Fasching, Peter A., De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V., Esteva, Francisco J., Martin, Miguel, Nusch, Arnd, Sonke, Gabe S., De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy

المصدر: The New England journal of medicine, 382 (6), 514-524 (2020)

مصطلحات موضوعية: Aged, Aminopyridines/administration & dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Breast Neoplasms/drug therapy/mortality, Drug Administration Schedule, Female, Fulvestrant/administration & dosage/adverse effects, Humans, Kaplan-Meier Estimate, Middle Aged, Postmenopause, Progression-Free Survival, Purines/administration & dosage/adverse effects, Receptor, ErbB-2, Receptors, Estrogen, Progesterone, oncology, Human health sciences, Sciences de la santé humaine, Oncologie

العلاقة: urn:issn:0028-4793; urn:issn:1533-4406; https://orbi.uliege.be/handle/2268/245119Test; info:hdl:2268/245119; scopus-id:2-s2.0-85079075053; info:pmid:31826360

الإتاحة: https://doi.org/10.1056/NEJMoa1911149Test
https://orbi.uliege.be/handle/2268/245119Test

المؤلفون: Ana Bosch, Mikkel G. Terp, Henrik J. Ditzel, Monique F. Hundebøl, Neil Portman, Lene E. Johansen, Kamila Kaminska, Gabriella Honeth, Carla Maria Lourenco Alves, Martin Bak, Odd L. Gammelgaard, Elgene Lim, Martina Tuttolomondo, Sidse Ehmsen

المصدر: Nature Communications
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9Test
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)

مصطلحات موضوعية: Fulvestrant/administration & dosage, endocrine system diseases, medicine.drug_class, Science, General Physics and Astronomy, Breast Neoplasms, Proto-Oncogene Proteins c-akt/genetics, Article, General Biochemistry, Genetics and Molecular Biology, Metastasis, Breast cancer, Breast Neoplasms/drug therapy, Cell Line, Tumor, Medicine, Humans, Molecular Targeted Therapy, neoplasms, Protein kinase B, Fulvestrant, Protein Kinase Inhibitors, Multidisciplinary, integumentary system, business.industry, Protein Kinase Inhibitors/administration & dosage, Endocrine therapy, Cancer, Cyclin-Dependent Kinase 4, General Chemistry, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 6/antagonists & inhibitors, Translational research, medicine.disease, Publisher Correction, Cyclin-Dependent Kinase 4/antagonists & inhibitors, Estrogen, Tumor progression, Drug Resistance, Neoplasm, Cancer research, Disease Progression, Drug Therapy, Combination, Female, biological phenomena, cell phenomena, and immunity, business, Proto-Oncogene Proteins c-akt, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909c54d06c561d241308a49e7f7f6e84Test
https://pubmed.ncbi.nlm.nih.gov/34531405Test

المؤلفون: Catherine Jane Bale, Rachel Butler, S Waters, Angela C. Casbard, Sarah Moon, Andrew Foxley, Ramachandran Venkitaraman, Catrin Cox, Johnathan Joffe, Tracie-Ann Madden, Fouad S Alchami, Margherita Carucci, Robert H. Jones, Chris Twelves, Pavel Bezecny, Sacha J Howell

المصدر: Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045Test(19)30817-4

مصطلحات موضوعية: 0301 basic medicine, Fulvestrant/administration & dosage, Drug Resistance, Neoplasm/drug effects, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Neoplasm Metastasis, Fulvestrant, Aged, 80 and over, Manchester Cancer Research Centre, Aromatase Inhibitors, Hazard ratio, Carcinoma, Ductal, Breast, Middle Aged, Prognosis, Survival Rate, Neoplasm Recurrence, Local/drug therapy, Oncology, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Receptors, Estrogen/metabolism, medicine.drug, Adult, medicine.medical_specialty, medicine.drug_class, Breast Neoplasms, Carcinoma, Lobular/drug therapy, Placebo, 03 medical and health sciences, Breast Neoplasms/drug therapy, Double-Blind Method, Internal medicine, medicine, Humans, Neoplasm Invasiveness, Pyrroles, Pyrimidines/administration & dosage, Survival rate, Aged, Salvage Therapy, Aromatase Inhibitors/pharmacology, Intention-to-treat analysis, Aromatase inhibitor, business.industry, Pyrroles/administration & dosage, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Lobular, 030104 developmental biology, Pyrimidines, Carcinoma, Ductal, Breast/drug therapy, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e1775f72f2c39bba92c189237cd97Test
https://pubmed.ncbi.nlm.nih.gov/32359499Test